Augtyro (Repotrectinib) Patent Expiration, LOE Window & CMS Spending
Augtyro (Repotrectinib) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2036-07-05 (last listed 2036-07-24), 0 AB generics, $13.3M 2024 CMS Part D & Medicaid spend, and $30,740 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bristol Myers Squibb |
| FDA Application & Pathway | N218213 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2036-07-05 |
| Last Listed Patent or Exclusivity Date | 2036-07-24 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $13.3M |
| 2024 Medicare Part D Spend | $9.8M |
| 2024 Medicaid Spend | $3.5M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($30,740 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.